Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...

Sangamo (SGMO) announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene ...

Sangamo Therapeutics (NASDAQ:SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate isaralgagene civaparvovec, or ST-920, in the treatment of Fabry disease. The ...

Now Gilead is spending a further $150 million upfront to access the cutting edge gene-editing technology of another Californian biotech, Sangamo. The ambition for this cancer-focused collaboration ...

RICHMOND, Calif. - Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company with a market capitalization of $263 million, has announced promising updated results from its Phase 1/2 STAAR ...

in a Sangamo Conference matchup with Pleasant Plains. “It really sucked not being able to play, but I think I worked hard to get better and I feel great.” Need a break? Play the USA TODAY ...

Publisher Bandai Namco and developer Media.Vision have announced Digimon Story: Time Stranger for PlayStation 5, Xbox Series, and PC (Steam). It will launch in 2025.

The Nintendo Switch 2 price has reportedly been revealed, and if the report is accurate, the Nintendo Switch 2 is set to be far more expensive than the current Switch. It has been over two weeks ...